Почетна › Рак јајника › Minesota › Minneapolis
Kliničke studije za Рак јајника u gradu Minneapolis, MN
23 studija za Рак јајника traži učesnike na lokacijama u gradu Minneapolis i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
Тражи се учесникФаза 1
- University of Minnesota, Minneapolis
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Тражи се учесникФаза 3
- Masonic Cancer Center, University of Minnesota, Minneapolis
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Тражи се учесникФаза 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 ми удаљено
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Тражи се учесникФаза 3
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Health Partners Inc, Minneapolis
- и још 2
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Тражи се учесник
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Health Partners Inc, Minneapolis
- и још 2
The Vanguard Study: Testing a New Way to Screen for Cancer
Тражи се учесникЗдраве особе су добродошле
- Minneapolis VA Medical Center, Minneapolis
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Тражи се учесникФаза 3
- Minnesota Oncology Hematology PA, Minneapolis
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Тражи се учесникФаза 1/2
- M Health Fairview University of Minnesota Medical Center, Minneapolis
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 2
- Health Partners Frauenshuh Cancer Center, Saint Louis Park · 5 ми удаљено
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Тражи се учесникФаза 2
- University of Minnesota - Minneapolis /ID# 275718, Minneapolis
- Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 274780, Saint Louis Park · 5 ми удаљено
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Тражи се учесникФаза 1
- University of Minnesota, Minneapolis
Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
Тражи се учесникЗдраве особе су добродошле
- University of Minnesota, Minneapolis
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Тражи се учесникФаза 2
- University Of Minnesota /ID# 277850, Minneapolis
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Тражи се учесникФаза 2
- Minnesota Oncology-Minneapolis, Minneapolis
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1
- University of Minnesota Masonic Cancer Center, Minneapolis
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Тражи се учесникФаза 1/2
- University of Minnesota/Masonic Cancer Center, Minneapolis
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Тражи се учесникФаза 1
- Normunity Investigational Site, Minneapolis
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Тражи се учесникФаза 2
- 518, Minneapolis
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Тражи се учесникФаза 2
- University of Minnesota - Masonic Cancer Center, Minneapolis
UNTOLD Ovarian Cancer Unmet Needs Survey
Тражи се учесникОпсервациона студија
- Masonic Cancer Center, Minneapolis
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Тражи се учесникФаза 1
- Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Тражи се учесникФаза 1
- University of Minnesota, Minneapolis
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Тражи се учесникФаза 2
- SCRI - Minnesota Oncology Hematology, P.A., Minneapolis
- University of Minnesota, Minneapolis
Studije za Рак јајника u drugim gradovima
- Houston, TX90 студија
- New York City, NY75 студија
- Boston, MA62 студија
- Los Angeles, CA53 студија
- Nashville, TN50 студија
- Arlington, VA47 студија
- Philadelphia, PA47 студија
- Columbus, OH39 студија
- St. Louis, MO37 студија
- Chicago, IL36 студија
- San Antonio, TX33 студија
- Pittsburgh, PA32 студија
Ostale studije u gradu Minneapolis
- Немалоклетни карцином плућа29 студија
- Рак дојке23 студија
- Рак простате22 студија
- Затајење срца22 студија
- Рак (све врсте)21 студија
- Карцином ендометријума20 студија
- Колоректални карцином20 студија
- Рак плућа20 студија
- Akutna mijeloidna leukemija19 студија
- Паркинсонова болест17 студија
- Коронарна болест срца15 студија
- Кардиоваскуларне болести15 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.